Earnings 20 Mar: China Risun 1907.HK (HKSE) HK$3.56 intraday 17 Mar 2026 margins key

The 1907.HK stock trades at HK$3.56 intraday on 17 Mar 2026 as investors position ahead of China Risun Group Limited’s earnings due 20 Mar 2026. Volume is unusually high at 119,281,000.00 shares versus an average of 26,916,027.00, reflecting strong interest and short-term volatility. The coming report will test margins and cash flow given a negative EPS of -0.02 and a high debt profile, making this earnings print a likely trigger for a sizable re-rate in Hong Kong’s Basic Materials group.

1907.HK stock: Earnings calendar and immediate catalysts

China Risun (1907.HK) has an earnings announcement scheduled for 20 Mar 2026. Market participants are watching margins, coking volumes and export demand for refined chemicals as the primary catalysts.

A strong beat on margins or guidance could relieve valuation concerns. Conversely, weak EBITDA or higher financing costs would likely push the stock lower given leverage.

1907.HK stock: Recent price action and liquidity

Intraday the share price is HK$3.56, a change of -1.11% on the session, with a day range HK$3.42–HK$3.87 and a year range HK$2.15–HK$3.98. Relative volume is 5.73, showing outsized trading interest versus the average.

Price averages sit above multi-month levels: 50-day average HK$2.52 and 200-day average HK$2.43, supporting a technically stronger near-term trend despite today’s pullback.

1907.HK stock: Financials, margins and valuation

On trailing metrics China Risun posts EPS -0.02 and a negative PE (reported -188.00), while price-to-sales is 0.33 and price-to-book is 1.14. Free cash flow yield is strong at 17.28%, but net income growth was negative last year, with EPS down roughly 97.58% year-on-year.

Balance sheet risks include a debt-to-equity of 2.79 and a current ratio of 0.62, leaving the company sensitive to interest costs. Analysts should weigh solid cash conversion against high leverage when modelling the next quarter.

1907.HK stock: Technicals and trading signals

Momentum indicators are overheated: RSI 82.73 and MFI 97.56, flagging short-term overbought conditions. ADX at 37.31 implies a strong trend, while MACD histogram at 0.12 shows positive momentum erosion.

Key intraday support sits near the day low HK$3.42 and the 50-day mean HK$2.52. Traders should use tight risk controls: a break below HK$3.42 increases the chance of a re-test of the 200-day average HK$2.43.

Meyka AI rates 1907.HK with a score out of 100 and forecast

Meyka AI rates 1907.HK stock with a score of 60.91 out of 100 (Grade: B, Suggestion: HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.

Meyka AI’s forecast model projects a 12-month price of HK$1.77, versus the current HK$3.56, implying an estimated downside of -50.42%. Forecasts are model-based projections and not guarantees.

1907.HK stock: Risks, sector context and what to watch

Risks include high leverage, thin short-term liquidity ratios, and volatile commodity prices that affect coke and chemical margins. The Basic Materials sector average ROE is higher than China Risun’s metrics, placing extra pressure on operational improvements.

Watch for commentary on coking capacity utilisation, caprolactam and benzene spreads, and any guidance on debt refinancing ahead of the quarter close.

Final Thoughts

China Risun (1907.HK) arrives at earnings on 20 Mar 2026 with mixed signals: a current price of HK$3.56, strong intraday volume (119,281,000.00), and technically overbought momentum. Core financials show reliable free cash flow but elevated leverage with debt-to-equity at 2.79 and a current ratio of 0.62, making the company vulnerable to margin compression or higher interest costs. Our Meyka grade places the stock at 60.91/100 (B, HOLD) after comparing sector benchmarks, growth trends and fundamental metrics. Meyka AI’s forecast model projects HK$1.77 for the next 12 months, an implied downside of -50.42% versus today’s price; this underscores valuation risk if results miss expectations. Earnings on 20 Mar 2026 will be decisive: a clear beat and guidance on deleveraging could re-rate the shares, while weak results would likely accelerate downside toward the HK$2.40–HK$2.50 support band. Investors should treat this as a catalyst-driven trade and use strict position sizing ahead of the report. Meyka AI provides this as AI-powered market analysis, not investment advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.